Rumor from a reliable source says MK-3475 (pembrolizumab) could be approved as early as mid summer.
Does this source also mention any restrictions, such as prior IPI fail and/or BRAF therapies if BRAF positive?
All things are possible through God!
He did not give any more info. --- but I research those questions daily --- I hope the individual oncologist can make that decision.
Catherine Poole at MIF has been trying to gather information from her contacts about this and put up a post this morning with some information here:
On a more favorable note --- When looking at this report, it looks like patients who are IPI untreated do better that IPI treated patients when given pembrolizumab -----
Favorable for some, I suppose...
How is that favorable if they require you to have IPI before you can get PD1!
Perhaps with all the new test results Merck will allow melanoma patients to take pembrolizumab regardless of having been previously treated with IPI. I know that some patients opted not to take the IPI for other health reasons. Allowing those patients access to pembrolizumab seem like a no brainer based on the current data.
It is up to the FDA to decide, be sure to write or call them or your congressman
Meet and talk to others about melanoma in our forums:
See also: History of the MPIP Forum
–CURE OM Forum
Or, visit the MRF Chat Room!
Questions to Ask Your Doctor
Email the MRF Nurse
Get matched with a Phone Buddy
Get updates on melanoma research, education & advocacy
Helpline: (877) 673-6460
1411 K Street, NW Suite 800
Washington, DC 20005
(800) 673-1290 Office
(202) 347-9678 Fax
The Melanoma Research Foundation (MRF) is leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy.
The Melanoma Research Foundation is a 501(c)(3) non-profit organization.